key: cord-0945838-97kpph40
authors: Mutiawati, Endang; Fahriani, Marhami; Mamada, Sukamto S.; Fajar, Jonny Karunia; Frediansyah, Andri; Maliga, Helnida Anggun; Ilmawan, Muhammad; Emran, Talha Bin; Ophinni, Youdiil; Ichsan, Ichsan; Musadir, Nasrul; Rabaan, Ali A.; Dhama, Kuldeep; Syahrul, Syahrul; Nainu, Firzan; Harapan, Harapan
title: Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis
date: 2021-01-21
journal: F1000Res
DOI: 10.12688/f1000research.28393.1
sha: 749cd880f1ec655c9ea6c9ec96e7d287f5077032
doc_id: 945838
cord_uid: 97kpph40

Background: The present study aimed to determine the global prevalence of anosmia and dysgeusia in coronavirus disease 2019 (COVID-19) patients and to assess their association with severity and mortality of COVID-19. Moreover, this study aimed to discuss the possible pathobiological mechanisms of anosmia and dysgeusia in COVID-19. Methods: Available articles from PubMed, Scopus, Web of Science, and preprint databases (MedRxiv, BioRxiv, and Researchsquare) were searched on November 10th, 2020. Data on the characteristics of the study (anosmia, dysgeusia, and COVID-19) were extracted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Newcastle–Ottawa scale was used to assess research quality. Moreover, the pooled prevalence of anosmia and dysgeusia were calculated, and the association between anosmia and dysgeusia in presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was assessed using the Z test. Results: Out of 32,142 COVID-19 patients from 107 studies, anosmia was reported in 12,038 patients with a prevalence of 38.2% (95% CI: 36.5%, 47.2%); whereas, dysgeusia was reported in 11,337 patients out of 30,901 COVID-19 patients from 101 studies, with prevalence of 36.6% (95% CI: 35.2%, 45.2%), worldwide. Furthermore, the prevalence of anosmia was 10.2-fold higher (OR: 10.21; 95% CI: 6.53, 15.96, p < 0.001) and that of dysgeusia was 8.6-fold higher (OR: 8.61; 95% CI: 5.26, 14.11, p < 0.001) in COVID-19 patients compared to those with other respiratory infections or COVID-19 like illness. To date, no study has assessed the association of anosmia and dysgeusia with severity and mortality of COVID-19. Conclusion: Anosmia and dysgeusia are prevalent in COVID-19 patients compared to those with the other non-COVID-19 respiratory infections. Several possible mechanisms have been hypothesized; however, future studies are warranted to elucidate the definitive mechanisms of anosmia and dysgeusia in COVID-19. Protocol registration: PROSPERO CRD42020223204.

searched on November 10th, 2020. Data on the characteristics of the study (anosmia, dysgeusia, and COVID-19) were extracted following Introduction Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was initially identified in late December 2019 in Wuhan, Hubei Province, Republic of China 1,2 . This viral pandemic rapidly spread worldwide, infecting more than 60 million people, causing more than 1 million deaths 3 , and severely affecting the global healthcare system 4,5 . Several drugs have been repurposed for treating COVID-19 5-9 ; however, no drug has been recommended or approved by the World Health Organization (WHO). The common symptoms of COVID-19 include dry cough, fever, dyspnea, fatigue, anorexia, diarrhea, chest pain, headache, and muscle ache 10,11 . In particular, two manifestations have been increasingly identified among asymptomatic people that later tested positive for the presence of SARS-CoV-2: anosmia and dysgeusia 12 . Remarkably, previous studies reported that these olfactory issues were reported in 11.8% of COVID-19 cases before other symptoms occured 13-15 .

Anosmia, a severe condition of hyposmia, is a part of olfactory dysfunction where the person is unable to sense smell or detect odor 16 . Dysgeusia is a sensory dysfunction where the individual loses the perception of taste 17 . The British Association of Otorhinolaryngology reported that both dysfunctions varied from 3-20% among COVID-19 patients 18 . A previous study among 42 patients revealed that more than a third presented anosmia and dysgeusia 19 . A higher percentage of anosmia and dysgeusia cases were also reported 20 . Furthermore, another study reported that anosmia in COVID-19 is related to the enlargement of bilateral olfactory bulb edema 21 .

This evidence may be crucial in the present COVID-19 pandemic. As the real-time reverse transcriptase polymerase chain reaction (RT-PCR) test has certain limitations for screening, the manifestation of anosmia and dysgeusia could be used as an early warning for practitioners or clinicians to build a rationale to reach a firm conclusion on patients with SARS-CoV-2 infection 22,23 . Additionally, a recent study reported that anosmia and dysgeusia are among the earliest symptoms observed in COVID-19 patients 24 ; however, in-depth analysis of this dysfunction and its relation to the pathogenesis, severity, and mortality of COVID-19 is missing from the literature. Thus, the present study aimed to summarize the global evidence of anosmia and dysgeusia among COVID-19 patients, in order to assess their association with the severity and mortality of the disease, and provide a comprehensive review related to the possible pathogenesis of anosmia and dysgeusia in SARS-CoV-2 infection.

To comprehensively calculate the cumulative prevalence of anosmia and dysgeusia in SARS-CoV-2 infection worldwide, a systematic review was conducted following guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 25 . The protocol of this systematic review has been registered at PROSPERO (CRD42020223204).

Eligibility criteria of studies All articles reporting anosmia and dysgeusia as the symptom of COVID-19 were included. COVID-19 case was defined by a positive RT-PCR for SARS-CoV-2 from either nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage, or cerebrospinal fluid. All cross-sectional, retrospective, and prospective studies that randomly sampled COVID-19 cases from community or hospitals were considered eligible; whereas case reports and case series, including all editorials, reviews, and commentaries, were excluded. Studies targeting specific groups such as pregnant females, children, and other groups, were excluded. Only articles written in English during 2019-2020 were included.

Three bibliographical databases (PubMed, Scopus, and Web of Science) and three preprint databases (MedRxiv, BioRxiv, and Researchsquare) were used to identify the potential articles (as of November 10th, 2020). The search criteria were as follows. PubMed ([Title] "SARS-CoV-2" OR "COVID-19" OR "Wuhan coronavirus" OR "Wuhan virus" OR "novel coronavirus" OR "nCoV" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus disease 2019 virus" OR "2019-nCoV" OR "2019 novel coronavirus" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus" OR "coronaviruses" OR "SARS 2" OR "2019-nCoV acute respiratory disease" OR "novel coronavirus pneumonia" OR "COVID") AND ([All] "Anosmia" OR "smell loss" OR "smell dysfunction" OR "smell impairment" OR "hyposmia" OR "dysosmia" OR "olfactory dysfunction" OR "olfactory disorder") AND ("dysgeusia" OR "taste loss" OR "taste dysfunction" OR "taste impairment" OR "gustatory dysfunction" OR "gustatory disorder" OR "hypogeusia" OR "ageusia"). Scopus ([Title] "SARS-CoV-2" OR "COVID-19" OR "Wuhan coronavirus" OR "Wuhan virus" OR "novel coronavirus" OR "nCoV" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus disease 2019 virus" OR "2019-nCoV" OR "2019 novel coronavirus" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus" OR "coronaviruses" OR "SARS 2" OR "2019-nCoV acute respiratory disease" OR "novel coronavirus pneumonia" OR "COVID") AND ([All] "Anosmia" OR "smell loss" OR "smell dysfunction" OR "smell impairment" OR "hyposmia" OR "dysosmia" OR "olfactory dysfunction" OR "olfactory disorder") AND ("dysgeusia" OR "taste loss" OR "taste dysfunction" OR "taste impairment" OR "gustatory dysfunction" OR "gustatory disorder" OR "hypogeusia" OR "ageusia"). Web of Science ([Title] "SARS-CoV-2" OR "COVID-19" OR "Wuhan coronavirus" OR "Wuhan virus" OR "novel coronavirus" OR "nCoV" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus disease 2019 virus" OR "2019-nCoV" OR "2019 novel coronavirus" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus" OR "coronaviruses" OR "SARS 2" OR "2019-nCoV acute respiratory disease" OR "novel coronavirus pneumonia" OR "COVID") AND ([All] "Anosmia" OR "smell loss" OR "smell dysfunction" OR "smell impairment" OR "hyposmia" OR "dysosmia" OR "olfactory dysfunction" OR "olfactory disorder") AND ([All] "dysgeusia" OR "taste loss" OR "taste dysfunction" OR "taste impairment" OR "gustatory dysfunction" OR "gustatory disorder" OR "hypogeusia" OR "ageusia").

Moreover, we searched the preprint servers MedRxiv, BioRxiv, and Researchsquare for non-peer-reviewed articles. Data were extracted from the articles as well as supplementary materials. Reference lists from the eligible articles were retrieved for further relevant studies.

The information of identified articles was imported into EndNote X9 (Thompson Reuters, Philadelphia, PA, USA). Duplicates between databases were removed. To identify eligible studies, the retrieved articles were screened based on title and abstract. The potentially eligible studies were then fully reviewed by two authors (MF and JKF). After reviewing the full texts, the eligibility of each study was decided.

Information of study characteristics, study site, study design, number of patients with anosmia, number of patients with dysgeusia, and COVID-19 characteristics such as number of patients, severity, and outcome were collected.

The primary outcomes were: (a) the global incidence of anosmia in COVID-19 patients; (b) the global incidence of dysgeusia in COVID-19 patients; (c) the association of anosmia with the severity of COVID-19; (d) the association of dysgeusia with the severity of COVID-19; (e) the association of anosmia with mortality of COVID-19; and (f) the association of dysgeusia with mortality of COVID-19. Moreover, this review was conducted to provide the possible pathogenesis of anosmia and dysgeusia in SARS-CoV-2 infection.

The cumulative prevalence rate of anosmia and dysgeusia was calculated for COVID-19 cases by dividing the number of COVID-19 cases with anosmia by the total number of COVID-19 cases with and without anosmia, and was expressed as a percentage (%) with 95% confidence intervals (95% CI). Pooled odds ratios (OR) and 95% CI were calculated to assess the association of anosmia and the occurrence of SARS-CoV-2 compared to non-SARS-CoV-2 respiratory infections. The same method was used for dysgeusia. The pooled OR and 95% CI were presented in a forest plot.

Critical assessment was conducted for the study setting and diagnosis of SARS-CoV-2 to reduce the bias. The Newcastle-Ottawa scale (NOS) 26 was used as critical appraisals to assess the quality of eligible studies. Prior to analysis, gathered data from studies were evaluated for heterogeneity and potential publication bias.

To assess the association between anosmia or dysgeusia and the presence of SARS-CoV-2, Z test was performed (p < 0.05 was considered statistically significant). Q test was used to evaluate the heterogeneity among studies, and the data with heterogeneity was analyzed using a random effect model. The reporting and publication bias were assessed using Egger's test and a funnel plot (p < 0.05 was considered having potential for publication bias). The data were analyzed using Review Manager version 5.3 27 .

In total, 691 articles (660 reviewed articles and 31 preprint articles) were identified through the databases; of these, 182 articles were removed as duplicates. An additional 287 articles were excluded following a screening process of the titles and abstracts due to irrelevant studies, leaving 222 references (Figure 1 ). Full-texts of the remaining 222 references were retrieved and screened for eligibility, and this process excluded an additional 115 references as the inclusion criteria was not met. This exclusion included articles with no access 28,29 , RT-PCR not clearly stated in the text 30-45 , case reports 46-97 , case seriess [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] , repeated datasetss [114] [115] [116] [117] [118] , and studies in specific groups [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] . A complete assessment was conducted for 107 references.

The meta-analysis included 107 studies to calculate the prevalence of anosmia in COVID-19 patients. Additionally, 6 studies were excluded while calculating the prevalence of dysgeusia in COVID-19, thus leaving 101 eligible studies. In total, 20 and 16 studies were included to assess the association of anosmia and dysgeusia with the COVID-19 occurrence, respectively.

To calculate the prevalence of anosmia in COVID-19 cases, 107 studies were included comprising 32,142 COVID-19 patients, and anosmia was reported in 12,038 patients with a global pooled prevalence of 38.2% (95% CI: 36.5%, 47.2%). The list of the studies and the prevalence of anosmia in each study are presented in Table 1 .

In total, 30,901 COVID-19 patients from 101 studies were included to calculate the prevalence of dysgeusia in COVID-19. Dysgeusia was identified in 11,337 out of 30,901 COVID-19 patients resulting in a cumulative prevalence of 36.6% (95% CI: 35.2%, 45.2%). The individual studies and the prevalence of dysgeusia from each study are listed in Table 2 .

In total, 20 studies comprising 1,213 COVID-19 cases with anosmia and 2,735 non-COVID-19 patients (mostly COVID-19-like symptoms with negative RT-PCR for SARS-CoV-2) were analyzed to investigate the association between 75 212 anosmia and the occurrence of COVID-19. Data suggested that anosmia was 10.2-fold more prevalent in patients with COVID-19 compared to those with COVID-19 like illness, OR 10.21 (95% CI: 6.53, 15.96) with p < 0.001 ( Figure 2 ).

In total, 16 studies comprising 1,342 COVID-19 cases with dysgeusia and 1,990 patients with other respiratory illness (COVID-19 like illness with negative RT-PCR for SARS-CoV-2) were included to assess the association between dysgeusia and the occurrence of COVID-19. Data suggested that dysgeusia was 8.6-fold more prevalent in patients with COVID-19 compared to those with other respiratory illness, with OR 8.61 (95% CI: 5.26, 14.11) and p<0.001 ( Figure 3 ).

Limited studies have assessed the association between anosmia and dysgeusia and the severity and mortality of COVID-19 cases. One study linked anosmia with a lower fatality rate and a lower ICU admission 240 .

The pooled prevalence of anosmia in our systematic review was 38.2% of 32,142 COVID-19 cases. This result was almost thrice the initial prevalence reported from Wuhan, China 174, 208 . This suggests that anosmia is a potential indicator of SARS-CoV-2 infection, and may be useful for screening and early identification of COIVD-19 patients, particularly asymptomatics 241 . Some countries, such as the UK and US have used anosmia as an indicator for preventive measure, wherein COVID-19 patient with anosmia should commence self-isolation 242-244 . Anosmia is not only present in COVID-19 patients, but also in patients with other respiratory diseases such as influenza, parainfluenza, Eipstein Barr virus, picornavirus, and rhinovirus [245] [246] [247] [248] . However, our study demonstrated that the prevalence of anosmia was 10.2-fold higher in COVID-19 patient than that in non-COVID-19 patient. During the previous pandemics, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), anosmia was rarely reported 249 . Only one study reported persistent anosmia after 2 years of recovery from SARS 250 . Another study reported that anosmia in COVID-19 patients varied based on ethnicity; anosmia in Caucasian is three times more prevalent than in Asian population 251 .

Dysgeusia was initially reported in 11.7% of patients who were discharged from Wuhan hospital, which persisted for at least four weeks. This result was lower than ours (36.6% out of 30,901 COVID-19 cases), which might be attributable to either lower dysgeusia prevalence in China or underestimation of this symptom itself 208 . Moreover, the prevalence of dysgeusia in COVID-19 patients was 8.6-fold higher than that in non-COVID-19 like illness. Herpes zoster and HIV have also been linked to gustatory dysfunction 252, 253 . Furthermore, another study reported that anosmia and dysgeusia have 82.5% predictive value for positive SARS-CoV-2 RT-PCR 254 .

Several mechanisms have been proposed to explain the emergence of anosmia in COVID-19 patients.

As several viral infections in the respiratory system display blockage of nasal airway or nasal congestion, this hypothesis was initially proposed. According to this mechanism, the interaction between the odorants and olfactory receptors is inhibited by certain obstructions, thereby impairing the subsequent smelling processes 255 . This condition results in anosmia. The obstruction could be caused by nasal discharge or by inflammation occurring in the nasal cavity 256 ; however, this hypothesis can be presumably ruled out. Moreover, several studies reported that anosmia is more prevalent than nasal congestion in COVID-19 patients 188, [256] [257] [258] [259] . Interestingly, the incidence of rhinorrhea and nasal obstruction in SARS-CoV-2 infection is lower than other coronaviruses such as SARS-CoV and MERS-CoV 260 .

Furthermore, presumably, nasal obstruction is a secondary mechanism by which anosmia is induced in COVID-19 patients as the obstruction in viral infection typically occurs as a subsequent event after damage in the mucociliary system, thereby inhibiting the nasal discharge and leading to nasal obstruction. In certain viral infections, the mucociliary system operated by ciliated cells is impaired. A previous study reported that human coronavirus (HCoV) disrupted the nasal ciliated respiratory epithelium leading to impaired mucociliary escalator system 261 .

Smelling processes commence when the odorants bind to the olfactory sensory neurons (OSNs) in the olfactory epithelium located in the nasal cavity, which subsequently transmits this information through their axons to the olfactory bulb in the brain 262 . According to this concept, a viral attack on the receptor neurons eventually creates disturbances in the sense of smell; however, this hypothesis remains under debate as several recent studies reported the absence of angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS), the key factors for the virus to enter the cell 263 , in the OSNs [264] [265] [266] [267] . These findings are supported by another study carried out by Bryche et al., who demonstrated that SARS-CoV-2 was not detected in the OSNs of hamsters 266 .

Moreover, after comparing the duration between anosmia incidence in COVID-19 patients and the normal cellular regeneration process, this proposed mechanism should be reconsidered. Several studies reported that COVID-19related anosmia disappeared within 1-2 weeks, whereas regeneration of dead OSNs requires more than 2 week time period 188, 206, 255, 262, 268 . This discrepancy results in a temporary conclusion that COVID-19-related anosmia is not directly associated with the impairment of the OSNs.

The aforementioned dysfunction of OSNs and the mechanism by which SARS-CoV-2 directly affects the olfactory center via axonal transport of the neuron remains unclear, as the OSN lacks ACE2 and TMPRSS2 which hinders viral entry into the cell [264] [265] [266] [267] . Nevertheless, the possibility of olfactory center disruption caused by SARS-CoV-2 should not be overlooked as the cause of anosmia, since a previous study concluded that human ACE2 (hACE2)-transgenic mice suffered from brain infection after intranasal inoculation with SARS-CoV 269 . The study found that the brain infection commenced from the olfactory bulb, which is the axonal trajectory pathway of the OSNs 269 . This finding suggests that SARS-CoV-2 might also first utilize another structure in the nasal cavity before it is transported into the OSNs.

As OSN does not express ACE2 and TMPRSS2, the virus should use another pathway to infect the olfactory system. Numerous studies have established the expression of these SARS-CoV-2 entry proteins in several supporting cells in olfactory epithelium, that is, Bowman's gland cells, horizontal basal cells, olfactory bulb pericytes, mitral cells, sustentacular cells, and microvillar cells [264] [265] [266] [267] . Of these supporting cells, the sustentacular cells have gained immense attention as the initial site of SARS-CoV-2 infection in the olfactory epithelium. In addition to their higher expression of ACE2 and TMPRSS2 than the others, sustentacular cells are located on the surface of the nasal cavity making them vulnerable to exposure to the external environment 264, 267 .

Notably, sustentacular cells act as supporting cells and promote olfactory neuron in the olfactory system. These cells detoxify harmful odorants, promote odorant-receptor binding, and provide nutritional substances to support the action of olfactory receptor neurons 255, 264 . Considerably, it is plausible to suggest that any damage occurring in sustentacular cells will in turn affect the olfactory epithelium and produce anosmia.

The corresponding regeneration time to the recovery of anosmia also supports the notion that sustentacular cell damage relates to anosmia caused by SARS-CoV-2. As the replenishment of dead OSNs does not correspond to the duration of COVID-19related anosmia within 1-2 weeks, the regeneration of sustentacular cells seems to be in line with that time frame 264, 266, 268 .

Furthermore, this hypothesis is supported by a recent study conducted by Bryche et al., who reported that SARS-CoV-2 was accumulated in sustentacular cells but not in the OSNs 266 . The olfactory epithelial damage and sustentacular cell loss occurred 2 days after instilling SARS-CoV-2 intranasally in golden Syrian hamsters 266 .

It is worth noting that the cytokine storm in COVID-19 is strongly associated with organ dysfunctions, including OSNs 232 . The dysfunction in this structure can lead to disturbance in the sense of smell 270 . Torabi et al. suggested that proinflammatory cytokines, particularly tumor necrosis factor a (TNF-α), may lead to COVID-19-induced anosmia 271 . Another proinflammatory cytokine, interleukin-6 (IL-6), increased in cases presenting with anosmia 232, 272 .

The mechanism used by these cytokines, in particular IL-6, to produce anosmia is not fully understood. Cazzolla et al. suggested that this effect can be caused by either peripheral or central action of the cytokines 232 . In the periphery, IL-6 may induce apoptosis of ciliary neuronal cells in the olfactory epithelium 272 , whereas in its central action, the olfactory center in the brain is attacked by the cytokine as a result of virus infection 232 .

Although gustatory impairment is always displayed concomitantly with olfactory dysfunction, this symptom has a relatively different mechanism and is often distantly linked to the latter symptom. Several hypotheses have been proposed to explain the mechanism behind the emergence of dysgeusia in COVID-19 patients.

Considering the close relationship between the olfactory and gustatory system both peripherally and centrally, smell and taste dysfunction in COVID-19 often occurs concomitantly 256, 273 . This hypothesis describes dysgeusia as a secondary event of olfactory dysfunction 274 ; however, several studies revealed that the percentage of dysgeusia in COVID-19 patients is higher than symptoms related to olfactory dysfunction 188, 275 . Based on this finding, another mechanism may be involved in inducing SARS-CoV-2-related dysgeusia. Furthermore, COVID-19-induced dysgeusia could also occur when there is certain damage in the cranial nerves responsible for gustatory transmission (cranial nerve VII, IX, and X) 276 . Among these nerves, SARS-CoV-2 exposure to cranial nerve VII has gained immense attention. Based on this hypothesis, the virus initially colonizes the nasopharynx structure, then moves to the Eustachian tube, and eventually reaches the middle ear where the virus gets access to chorda tympani and causes dysgeusia 276 .

Another interesting hypothesis underlying dysgeusia in COVID-19 is related to zinc deficiency 276 . This hypothesis was developed as zinc is an important mineral in carbonic anhydrase, which is pivotal in maintaining taste sensation 277 . Interestingly, one study reported that zinc level in patients with SARS-CoV-2 infection was significantly lower compared to that in the healthy control groups 278 . Alterations in the sense of taste after being treated with certain treatments, such as irradiation in cancer patients 279, 280 , could be prevented by zinc supplementation. Moreover, dengue fever virus and human immunodeficiency virus replication could be inhibited by zinc chelation 281, 282 . Furthermore, pharmacological agents influencing ACE2 activity are associated with taste disturbances 283, 284 .

Nevertheless, this effect does not relate to zinc deficiency as these drugs do not influence both serum and salivary zinc concentrations 284 . Further investigation needs to be carried out to reveal the role of zinc in dysgeusia associated with COVID-19.

SARS-CoV-2 may produce dysgeusia via interaction with sialic acid receptors 232, 274, 285 . Sialic acid plays a pivotal role in the taste processing pathway as it is a component of the normal salivary composition 286 . Moreover, reduced amount of sialic acid impairs the ability to taste 287 . An in silico study revealed that SARS-CoV-2 could interact with the sialic acid receptor through its spike protein 288 . Previously, MERS-CoV was also reported to interact with this receptor 289 . Following this occupancy, the gustatory threshold increases, while gustatory particles degrade at a higher rate 274, 287 .

A previous study investigated the expression of ACE2 in various tissues in the oral cavity and found that the tongue had higher ACE2 expression in comparison to other tissues, such as buccal and gingival tissues 290 . This finding raised a hypothesis that SARS-CoV-2 could directly attack the taste buds in the tongue, initiating inflammatory responses, and would eventually alter the sense of taste 276 . It is proposed that the Toll-like receptor-mediated cascade and apoptosis are the subsequent events that could lead to taste dysfunction 276, 291 .

A previous study investigating SARS-CoV infection in rhesus macaques revealed that, initially, the salivary gland was attacked by the virus 292 . As the human salivary gland expresses a high level of ACE2 293 , it is reasonable to pay more attention to the vulnerability of this gland against SARS-CoV-2 exposure. Disruption in the activity of the salivary gland would produce either imbalance in salivary composition or impairment of salivary flow, which could ultimately result in dysgeusia 276 .

Out of 32,142 and 30,901 COVID-19 cases studied for anosmia and dysgeusia, respectively, the prevalence of anosmia was approximately 38.2%, whereas that of dysgeusia was 36.6%. Both of these symptoms were more common in COVID-19 compared to other respiratory infections (approximately 10 and 9 times, respectively). Several mechanisms have been proposed to explain the emergence of anosmia in COVID-19 patients including nasal airway obstruction, damage in OSNs, olfactory center damage in the brain, dysfunction of olfactory supporting cells, and inflammationrelated olfactory epithelium dysfunction. Furthermore, some possible pathogenesis of dysgeusia in SARS-CoV-2 infection has been proposed including cranial nerve dysfunction, zinc deficiency, virion interaction, and direct attack of the virus to several oral sites.

Undelying data All data underlying the results are available as part of the article and no additional source data are required. 

An update on SARS-CoV-2/ COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Epub 2020/06/26. PubMed Abstract|Publisher Full Text|Free Full Text 3. Worldometers: COVID-19 coronavirus pandemic. Reference Source

Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

Encephalomyelitis associated with Covid-19 infection: case report

PubMed Abstract|Publisher Full Text

Epidemiological Chronicle of the First Recovered Coronavirus Disease Patient From Panama: Evidence of Early Cluster Transmission in a High School of Panama City. Front. Public Health 2020: 8. PubMed Abstract|Publisher Full Text|Free Full Text 73

Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature

PubMed Abstract|Publisher Full Text|Free Full Text

Guillain-Barre syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing

PubMed Abstract|Publisher Full Text|Free Full Text

Headache and pleocytosis in CSF associated with COVID-19: case report

PubMed Abstract|Publisher Full Text|Free Full Text

Hypogeusia as the initial presenting symptom of COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text 78. Pallanti S: Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology

Meningitis as an Initial Presentation of COVID-19: A Case Report

PubMed Abstract|Publisher Full Text|Free Full Text

Miller Fisher syndrome and COVID-19: Is there a link

PubMed Abstract|Publisher Full Text|Free Full Text

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

PubMed Abstract|Publisher Full Text

Multiple sclerosis following SARS-CoV-2 infection

COVID-19 and Older People in Asia: AWGS Calls to Actions

PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory bulb magnetic resonance imaging in SARS-CoV-2-induced anosmia in pediatric cases

Oral ulceration and blistering in patients with COVID-19

Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient

Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

PubMed Abstract|Publisher Full Text|Free Full Text

SARS-CoV-2 can induce brain and spine demyelinating lesions

PubMed Abstract|Publisher Full Text|Free Full Text

Second episode of COVID-19 in health professionals: Report of two cases

PubMed Abstract|Publisher Full Text|Free Full Text

Severe olfactory and gustatory dysfunctions in a Japanese pediatric patient with coronavirus disease (COVID-19)

A special symptom of olfactory dysfunction in coronavirus disease 2019: report of three cases

PubMed Abstract|Publisher Full Text|Free Full Text

Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab

Thoracoscopic bullectomy for persistent air leak in a 14-year-old child with COVID-19 bilateral pulmonary disease

PubMed Abstract|Publisher Full Text

Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis

PubMed Abstract|Publisher Full Text|Free Full Text

Type 1 diabetes onset triggered by COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Unilateral laterothoracic exanthem in association with coronavirus disease 2019

PubMed Abstract|Publisher Full Text|Free Full Text

Vasculitis-related stroke in young as a presenting feature of novel coronavirus disease (COVID19) -Case report

Ageusia and anosmia, a common sign of COVID-19? A case series from four countries

PubMed Abstract|Publisher Full Text|Free Full Text

Anosmia as a presenting symptom of SARS-CoV-2 infection in healthcare workers -A systematic review of the literature, case series, and recommendations for clinical assessment and management

PubMed Abstract|Publisher Full Text

Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom

PubMed Abstract|Publisher Full Text|Free Full Text

Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss

Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement

PubMed Abstract|Publisher Full Text|Free Full Text

Fetal deaths in pregnancies with SARS-CoV-2 infection in Brazil: A case series. Case Rep Womens Health

PubMed Abstract|Publisher Full Text|Free Full Text

Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients

Oral lesions in patients with SARS-CoV-2 infection: could the oral cavity be a target organ? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2020. PubMed Abstract|Publisher Full Text|Free Full Text

Patterns of myocardial involvement in children during COVID-19 pandemic: Early experience from northern Italy

PubMed Abstract|Publisher Full Text|Free Full Text

Prognosis of olfactory and gustatory dysfunctions in COVID-19 patients: A case series

Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona

PubMed Abstract|Publisher Full Text|Free Full Text

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden

SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus

PubMed Abstract|Publisher Full Text|Free Full Text

SARS-CoV-2 infection in persons living with HIV: A single center prospective cohort

Trend of Olfactory and Gustatory Dysfunction in COVID-19 Patients in a Quarantine Facility

Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients

PubMed Abstract|Publisher Full Text|Free Full Text

Gustatory Dysfunction: A Highly Specific and Smell-Independent Symptom of COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2 positive subjects

Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study

PubMed Abstract|Publisher Full Text|Free Full Text

Remote psychophysical evaluation of olfactory and gustatory functions in early-stage coronavirus disease 2019 patients: The Bologna experience of 300 cases

PubMed Abstract|Publisher Full Text|Free Full Text

Validation of a selfadministered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine

PubMed Abstract|Publisher Full Text|Free Full Text

A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study

PubMed Abstract|Publisher Full Text

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort

PubMed Abstract|Publisher Full Text|Free Full Text

Does COVID-19 cause permanent damage to olfactory and gustatory function? Med Hypotheses

Emergence and Evolution of Olfactory and Gustatory Symptoms in Patients with COVID-19 in the Outpatient Setting

PubMed Abstract|Publisher Full Text|Free Full Text

Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis

Incomplete and late recovery of sudden olfactory dysfunction in COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Objective evaluation of the nasal mucosal secretion in COVID-19 patients with anosmia. Ir

Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed COVID-19 infection

Olfactory Bulb MRI and Paranasal Sinus CT Findings in Persistent COVID-19

Anosmia. Acad. Radiol. 2020. PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory bulb signal abnormality in patients with COVID-19 who present with neurologic symptoms

Paranasal sinuses computed tomography findings in anosmia of COVID-19

PubMed Abstract|Publisher Full Text

PREDICTIVE VALUE OF SMELL AND TASTE TEST VS PCR-RT SARS-COV-2 AND RAPID DIAGNOSTIC TESTS IN THE DIAGNOSIS OF INFECTION BY

A comparative study on the clinical features of COVID-19 with non-SARS-CoV-2 respiratory viral infections

Accuracy of Emergency Department Clinical Findings for Diagnosis of Coronavirus Disease

Acuteonset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based casecontrol study

PubMed Abstract|Publisher Full Text|Free Full Text

Analysis of imported cases of covid-19 in taiwan: A nationwide study

PubMed Abstract|Publisher Full Text|Free Full Text

Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched casecontrol study

PubMed Abstract|Publisher Full Text

Are Gastrointestinal Symptoms Specific for Coronavirus 2019 Infection? A Prospective Case-Control Study From the United States

Assessment of neurological manifestations in hospitalized patients with COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

PubMed Abstract|Publisher Full Text|Free Full Text

Chemosensory dysfunction in COVID-19 out-patients

Chemosensory Dysfunction in COVID-19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample. Otolaryngol. Head Neck Surg

PubMed Abstract|Publisher Full Text|Free Full Text

Chest x-rays findings in covid 19 patients at a university teaching hospital-a descriptive study

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

PubMed Abstract|Publisher Full Text|Free Full Text

Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019

PubMed Abstract|Publisher Full Text|Free Full Text

Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19

WOS:000544273300033. PubMed Abstract|Publisher Full Text|Free Full Text

Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study

PubMed Abstract|Publisher Full Text|Free Full Text

Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis

PubMed Abstract|Publisher Full Text|Free Full Text

Contemporary Analysis of Olfactory Dysfunction in Mild to Moderate Covid 19 Patients in A Tertiary Health Care Centre

PubMed Abstract|Publisher Full Text|Free Full Text

Publisher Full Text

COVID-19 Viral Load in the Severity of and Recovery From Olfactory and Gustatory Dysfunction

PubMed Abstract|Publisher Full Text|Free Full Text

COVID-19: comparative clinical features and outcome in 114 patients with or without pneumonia

Differential Diagnosis of COVID-19: Importance of Measuring Blood Lymphocytes, Serum Electrolytes, and Olfactory and Taste Functions

PubMed Abstract|Publisher Full Text

Dysosmia and dysgeusia in patients with COVID-19 in northern Taiwan

Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients

PubMed Abstract|Publisher Full Text|Free Full Text

Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic

PubMed Abstract|Publisher Full Text|Free Full Text

Early neurological manifestations of hospitalized COVID-19 patients

PubMed Abstract|Publisher Full Text|Free Full Text

Early recovery patterns of olfactory disorders in COVID-19 patients; a clinical cohort study

PubMed Abstract|Publisher Full Text|Free Full Text

Epidemiological And Clinical Characteristics Of Covid-19 Patients In Kenya

Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in

Epistaxis as a marker for severe acute respiratory syndrome coronavirus-2 status -A prospective study

PubMed Abstract|Publisher Full Text|Free Full Text

Evaluation of Olfactory Acuity in Patients with Coronavirus Disease

PubMed Abstract|Publisher Full Text|Free Full Text

Evolution of Olfactory Disorders in COVID-19 Patients

PubMed Abstract|Publisher Full Text|Free Full Text

Features of anosmia in COVID-19

Frequency and outcome of olfactory impairment and sinonasal involvement in hospitalized patients with COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross-Sectional Study

PubMed Abstract|Publisher Full Text|Free Full Text

Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia

PubMed Abstract|Publisher Full Text|Free Full Text

Headache characteristics in COVID-19 pandemic-a survey study

PubMed Abstract|Publisher Full Text|Free Full Text

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

PubMed Abstract|Publisher Full Text|Free Full Text

Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection

Loss of taste and smell are common clinical characteristics of patients with COVID-19 in somalia: A retrospective double centre study

PubMed Abstract|Publisher Full Text|Free Full Text

Loss of Taste and Smell as Distinguishing Symptoms

PubMed Abstract|Publisher Full Text|Free Full Text

Main symptoms in patients presenting in the COVID-19 period

PubMed Abstract|Publisher Full Text

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

PubMed Abstract|Publisher Full Text|Free Full Text

Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital

PubMed Abstract|Publisher Full Text

Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline

PubMed Abstract|Publisher Full Text

Neurological symptoms as initial manifestation of Covid-19-An observational study

PubMed Abstract|Publisher Full Text|Free Full Text

Neurosensory dysfunction: A diagnostic marker of early COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

New loss of smell and taste: Uncommon symptoms in COVID-19 patients in Nord Franche-Comte cluster, France

PubMed Abstract|Publisher Full Text|Free Full Text

New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects

PubMed Abstract|Publisher Full Text|Free Full Text

New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection

PubMed Abstract|Publisher Full Text|Free Full Text

Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases

Objective olfactory findings in hospitalized severe COVID-19 patients

PubMed Abstract|Publisher Full Text|Free Full Text

Ocular involvement in coronavirus disease 2019 (COVID-19): a clinical and molecular analysis

Olfactory and gustatory abnormalities in COVID-19 cases

PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study. Otolaryngol. Head Neck Surg

Olfactory and Gustatory Dysfunctions as a Clinical Manifestation of Coronavirus Disease

PubMed Abstract|Publisher Full Text

Olfactory and gustatory dysfunctions as a clinical presentation of mild-tomoderate forms of the coronavirus disease (COVID-19): a multicenter European study

PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life

PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects. Otolaryngol. Head Neck Surg. 2020. PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics

PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory Dysfunction in COVID-19 Patients: Prevalence and Prognosis for Recovering Sense of Smell. Otolaryngol. Head Neck Surg. 2020. PubMed Abstract|Publisher Full Text

Olfactory dysfunction in patients after recovering from COVID-19

Onset, duration, and persistence of taste and smell changes and other COVID-19 symptoms: longitudinal study in Israeli patients

Otolaryngologic Manifestation and Long-Term Outcome in Mild COVID-19: Experience from a Tertiary Care Centre in India

PubMed Abstract|Publisher Full Text|Free Full Text

Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection

Otolaryngological symptoms in COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

PubMed Abstract|Publisher Full Text|Free Full Text

Patterns of viral clearance in the natural course of asymptomatic COVID-19: Comparison with symptomatic non-severe COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Persistent Smell Loss Following Undetectable SARS-CoV-2. Otolaryngol

Predictive factors of COVID-19 in patients with negative RT-qPCR

PubMed Abstract|Publisher Full Text|Free Full Text

Predictive Value of Sudden Olfactory Loss in the Diagnosis of COVID-19

Predictors of disease duration and symptom course of outpatients with acute covid-19: a retrospective cohort study

Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

PubMed Abstract|Publisher Full Text|Free Full Text

Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study

Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients

Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study

PubMed Abstract|Publisher Full Text|Free Full Text

Prevalence and recovery time of olfactory and gustatory dysfunction in hospitalized patients with COVID-19 in Wuhan. China

Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID-19 patients

Prevalence of Anosmia and Ageusia in Patients with COVID-19 at a Primary Health Center

Prevalence Of Anosmia And Dysgeusia In Patients Of COVID-19 In A Dedicated Covid Hospital

Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: a cross-sectional study

Prevalence of New Onset Anosmia in COVID-19 Patients: Is The Trend Different Between European and Indian Population?

PubMed Abstract|Publisher Full Text|Free Full Text

Relationship between anosmia and hospitalisation in patients with coronavirus disease 2019: An otolaryngological perspective

PubMed Abstract|Publisher Full Text|Free Full Text

Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel

Self-reported anosmia and dysgeusia as key symptoms of coronavirus disease 2019

Self-reported olfactory loss associates with outpatient clinical course in COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Self-reported taste and smell disorders in patients with COVID-19: distinct features in China

Severe Coronavirus Disease-2019 in Children and Young Adults in the

Short-term follow-up of self-isolated covid-19 patients with smell and taste dysfunction in Greece: Two phenotypes of recovery

Silent disease and loss of taste and smell are common manifestations of SARS-COV-2 infection in a quarantine facility: Saudi Arabia

Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts

PubMed Abstract|Publisher Full Text|Free Full Text

Smell and taste disorders during COVID-19 outbreak: Cross-sectional study on 355 patients

Smell and taste disorders in Spanish patients with mild COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Smell and taste dysfunction in covid-19 is associated with younger age in ambulatory settings: A multicenter crosssectional study

PubMed Abstract|Publisher Full Text

Smell and taste recovery in coronavirus disease 2019 patients: A 60-day objective and prospective study

Smell dysfunction in COVID-19 patients: More than a yes-no question

PubMed Abstract|Publisher Full Text|Free Full Text

Smell dysfunction: a biomarker for COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Smell loss is a prognostic factor for lower severity of coronavirus disease 2019

PubMed Abstract|Publisher Full Text|Free Full Text

Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2

Symptomatology of COVID-19 from the otorhinolaryngology perspective: a survey of 223 SARS-CoV-2 RNA-positive patients

PubMed Abstract|Publisher Full Text|Free Full Text

Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6

Testing Olfactory and Gustatory Dysfunctions among Quarantine

PubMed Abstract|Publisher Full Text|Free Full Text

The close relationship between sudden loss of smell and COVID-19

The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection

PubMed Abstract|Publisher Full Text|Free Full Text

Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19

PubMed Abstract|Publisher Full Text|Free Full Text

Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study

Objective Olfactory Evaluation of Self-reported Olfactory Dysfunction in a Case Series of 86 COVID-19 Patients

PubMed Abstract|Publisher Full Text|Free Full Text

Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak

PubMed Abstract|Publisher Full Text|Free Full Text

Anosmia is associated with lower in-hospital mortality in COVID-19

PubMed Abstract. |PubMed Abstract|Publisher Full Text| Free Full Text

A Literature Systematic Review with Meta-Analysis of Symptoms Prevalence in Covid-19: the Relevance of Olfactory Symptoms in Infection Not Requiring Hospitalization

PubMed Abstract|Publisher Full Text|Free Full Text 242. Department of Health and Social Care: Statement from the UK Chief Medical Officers on an update to coronavirus symptoms

Ear N Throat Society of the United Kingdom (ENTUK): Loss of sense of smell as marker of COVID-19 infection

COVID-19 Anosmia Reporting Tool: Initial Findings. Otolaryngol. Head Neck

PubMed Abstract|Publisher Full Text

Identification of Viruses in Patients With Postviral Olfactory Dysfunction

PubMed Abstract|Publisher Full Text|Free Full Text

Coinfection with SARS-CoV-2 and influenza A virus

PubMed Abstract|Publisher Full Text|Free Full Text

COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia

Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster

PubMed Abstract|Publisher Full Text|Free Full Text

Neurological Complications of SARS-CoV

PubMed Abstract|Publisher Full Text|Free Full Text

Olfactory neuropathy in severe acute respiratory syndrome: report of A case

Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences

PubMed Abstract|Publisher Full Text|Free Full Text

Gustatory dysfunction after mandibular zoster

Taste and smell losses in HIV infected patients

PubMed Abstract|Publisher Full Text

Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients

Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection

Olfactory and gustatory abnormalities in COVID-19 cases

ENT manifestation in COVID-19 patients

PubMed Abstract|Publisher Full Text|Free Full Text

Otorhinolaryngological manifestations of COVID-19-A systematic review

The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol. Head Neck Surg

Aggregate Prevalence of Chemosensory and Sinonasal Dysfunction in SARS-CoV-2 and Related Coronaviruses

The effects of coronavirus on human nasal ciliated respiratory epithelium

A lifetime of neurogenesis in the olfactory system

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age

PubMed Abstract|Publisher Full Text|Free Full Text

Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients

Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters

SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium

PubMed Abstract|Publisher Full Text|Free Full Text 268. Schwob JE: Neural regeneration and the peripheral olfactory system

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Innate immune signaling in the olfactory epithelium reduces odorant receptor levels: modeling transient smell loss in COVID-19 patients

Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia

Interleukin 6 in hyposmia

PubMed Abstract|Publisher Full Text

Odor/taste integration and the perception of flavor

PubMed Abstract|Publisher Full Text

Potential pathogenesis of ageusia and anosmia in COVID-19 patients

Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study

Dysgeusia in COVID-19: Possible Mechanisms and Implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2020

Zinc deficiency and taste dysfunction; contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation

COVID-19: Poor outcomes in patients with zinc deficiency

PubMed Abstract|Publisher Full Text|Free Full Text

Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial

A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation

PubMed Abstract|Publisher Full Text

Zinc Chelation Specifically Inhibits Early Stages of Dengue Virus Replication by Activation of NF-κB and Induction of Antiviral Response in Epithelial Cells

Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G

PubMed Abstract|Publisher Full Text

The influence of hypotensive drugs on the taste sensitivity in patients with primary hypertension

Comparative study of taste disturbance by losartan and perindopril in healthy volunteers

PubMed Abstract|Publisher Full Text

Anosmia and ageusia associated with coronavirus infection (COVID-19) -what is known?

PubMed Abstract|Publisher Full Text|Free Full Text

Comparative lectin histochemistry on taste buds in foliate, circumvallate and fungiform papillae of the rabbit tongue

Reduced Salivary Mucin Binding and Glycosylation in Older Adults Influences Taste in an in vitro Cell Model

PubMed Abstract|Publisher Full Text|Free Full Text

In-Silico evidence for two receptors based strategy of SARS-CoV-2

Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Inflammation and taste disorders: mechanisms in taste buds

Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques

PubMed Abstract|Publisher Full Text|Free Full Text

Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection

PubMed Abstract|Publisher Full Text

Anosmia and dysgeusia in SARS-CoV-2 infection: Incidence, effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms -A systematic review and meta-analysis. figshare

Authors would like to thank HT Editorial Services in assisting the writing process.

Department of Surgery, New York Medical College, Valhalla, NY, USA Thank you for an interesting systematic review. This systematic review and meta-analysis aimed at evaluating the rate of anosmia and dysgeusia in patients with confirmed COVID-19 and their association with disease severity and mortality. The research question makes sense and the methodology chosen for statistical analysis is logical. The Introduction is comprehensible and easy to read, it clearly states the gap in the literature and the rationale behind this research question. The aim of the study was stated clearly. The Methods are well-formulated. Reporting of this review is compliant with the PRISMA guidelines. The search strategy is comprehensive, includes major databases as well as preprint servers. The details of the search strategy and the PRISMA flow diagrams were provided. Eligibility criteria and definitions were reported. Statistical analysis was adequate. The Results are well-written and clear. The findings of the statistical analysis were nicely summarized in tables and illustrated in forest plots. The Discussion is comprehensible and easy to read. The authors have provided interpretation of their findings, and clinical and scientific implications thereof. The authors have provided possible etiopathogenesis for anosmia and dysgeusia in COVID-19 patients. The Conclusion was justified by the statistical findings.In order to improve the manuscript, I have a few suggestions:There is some confusion between the terms incidence and prevalence. In fact, in the Methods under the Outcomes, the authors stated the primary outcomes to be incidence of anosmia and dysgeusia, whereas they described this metrics as prevalence in the rest of the manuscript. I believe neither of the terms fits the context. I would change these terms to rate, eg. anosmia rate (rate of anosmia) and dysgeusia rate (rate of dysgeusia).1.I would not use Newcastle-Ottawa scale for risk of bias assessment as it does not evaluate for heterogeneity due to the differences in the definitions of outcomes and interventions to measure the outcome. I would rather use ROBINS-I tool.2.I would address in the Discussion the reasons for substantial heterogeneity in the pooled 3.rates of anosmia and dysgeusia. I would consider heterogeneity in geographic locations and community types, heterogeneity in the definitions of anosmia and dysgeusia, and heterogeneity in the definitions of disease severity across the included studies.I would add a brief paragraph to the Discussion (last paragraph) and acknowledge the strengths and limitations of this study.

Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes

Are the conclusions drawn adequately supported by the results presented in the review? Yes 

Department of Medical Laboratory Science, Babcock University, Ilishan-Remo, NigeriaThe present study examined the global prevalence of anosmia and dysgeusia in COVID-19 patients, their association with severity and mortality of COVID-19, as well as the possible pathobiological mechanisms of anosmia and dysgeusia in COVID-19. Authors reported a global prevalence of 38.2% and 36.6% for anosmia and dysgeusia, respectively. Identified potential mechanisms for anosmia include: Obstruction in the nasal airway, damage in olfactory sensory neurons, olfactory center damage in the brain, olfactory supporting cells dysfunction and inflammation-related olfactory epithelium dysfunction. On the other hand, the subsequent effect of cranial nerves dysfunction, Zinc deficiency, SARS-CoV-2-bound sialic acid, Direct attack on several oral sites are opined to be responsible for the dysgeusia.The work is okay and the findings are worth-sharing with the scientific community. The introduction is considered satisfactory. Authors provided background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study. They also identified the existing gap in knowledge that needs to be filled. The methodology section was clearly presented to allow the reproduction of the study. Discussion and Conclusion were well written. However, the limitation of the study was not clearly stated. And except, the association of anosmia and dysgeusia with severity and mortality is properly discussed in the study, it should be deleted from the objectives. 

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. The analysis on the assessment of the association with the severity and mortality of the disease is very short and needs more data to be reported.

In the conclusion the authors did not include all the objectives of the study.

No statement on the association anosmia and dysgeusia with severity and mortality as stated in the objectives.

My recommendation would be to add the limitations of this study.

Are sufficient details of the methods and analysis provided to allow replication by others? Yes

Are the conclusions drawn adequately supported by the results presented in the review? Partly